Aberrant methylation of the TDMR of the GTF2A1L promoter does not affect fertilisation rates via TESE in patients with hypospermatogenesis by Sugimoto Kazuhiro et al.
Aberrant methylation of the TDMR of the
GTF2A1L promoter does not affect fertilisation
rates via TESE in patients with
hypospermatogenesis
著者 Sugimoto Kazuhiro, Koh Eitetsu, Iijima
Masashi, Taya Masaki, Maeda Yuji, Namiki Mikio
journal or
publication title









Aberrant methylation of the tissue-specific differentially methylated region 
(TDMR) at the GTF2A1L promoter does not affect fertilization rates via 
testicular sperm extraction in patients with hypospermatogenesis 
 
Running title:  
Aberrant methylation of TDMR in GTF2A1L 
 
 
Kazuhiro Sugimoto, Eitetsu Koh, Masashi Iijima, Masaki Taya, Yuji Maeda, 
Mikio Namiki 
 
Departments of Integrative Cancer Therapy and Urology, Andrology Unit,  
Kanazawa University Graduate School of Medical Science, Takara, 
Kanazawa 920-8641, Japan 
 
Correspondance: 
    Eitetsu Koh  M.D., Ph.D.,  
Department of Integrative Cancer Therapy and Urology, Kanazawa University 
Graduate School of Medical Science 
13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan 





There is increasing evidence of a relationship between epigenetic regulation 
and male infertility. GTF2A1L promoters contain the DNA methylation site of a 
tissue-specific differentially methylated region (TDMR).  Eighty-six patients 
with secretory azoospermia were assessed by the DNA methylation state of 
CpG islands in the GTF2A1L promoter using testicular genome DNA. Based 
on histological criteria, 26 of the 86 patients had normal spermatogenesis 
(controls), 17 had hypospermatogenesis, and 26 had a Sertoli cell-only 
phenotype or tubular sclerosis. GTF2A1L TDMR methylation was significantly 
lower in testes DNA from control samples than from hypospermatogenic 
samples (P=0.029). Patients with hypospermatogenesis were divided into two 
subgroups: high DNA methylation (HM, n=5), and low methylation (LM, n=12). 
The GTF2A1L TDMR methylation rate differed significantly between HM and 
LM groups (P=0.0019), and GTF2A1L expression was significantly higher 
among LM than HM patients (P=0.023). High TDMR methylation was 
correlated with low levels of gene expression. Both groups had relatively good 
outcomes with respect to sperm retrieval and fertilization, pregnancy, 
childbirth rates. We observed that aberrant expression of the GTF2A1L gene 
was not correlated with fertilization rates. The TESE technique may be used 
to overcome male infertility due to aberrant TDMR methylation. 
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 Male factors of total infertility may account for up to 40−50% of infertile 
couples 1. There are many more cases of male infertility that are 
unreported. Testicular sperm extraction (TESE) and intracytoplasmic sperm 
injection (ICSI) are commonly used to overcome male infertility, and sperm 
retrieval is successful in 30−70% of patients with non-obstructive 
azoospermia.2  In hypoplasia, 97.7% had late spermatids/sperm recovered 
using assisted reproductive technique (ART). 3 In healthy males, infertility may 
have a number of unknown causes, including genetic or epigenetic disorders. 
Epigenetic modifications in particular result in stable or semi-stable 
changes in gene expression without affecting the nucleotide sequence of 
DNA.4, 5 DNA methylation plays a role in gene regulation during development, 
and has also been involved in genomic imprinting and X-inactivation. 
CpG dinucleotides, also known as CpG islands, are located in the 
promoter regions of many genes, and their DNA methylation state varies. 
CpG islands are generally not methylated during normal cell development, 
with the exception of imprinted genes. They are preferentially located at the 
start of gene transcripts and on the differentially methylated regions (DMRs) 
of imprinted genes.6 
However, tissue-specific differentially methylated regions (TDMRs) are 
a somewhat different category, identified by means of DNA methylation array 
methods, and are demethylated in some tissues and fully methylated in 
others.7, 8 Therefore, DNA methylation of TDMRs in gene loci causes 
transcriptional repression. 9-11 TDMRs are interspersed throughout the entire 
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genome and ensure that DNA methylation status corresponds to specific 
tissue types. 
Methylation analysis performed on testicular DNA has revealed 
numerous differentially methylated loci in the male germline.12, 13 Therefore, 
some genes with demethylated TDMRs are expressed in a tissue-specific 
manner. 14, 15 Numerous CpG islands containing TDMRs are potential 
methylation sites in normal cells and tissues. The expression of genes 
associated with identified TDMRs has been shown to correlate with 
methylation status. Thus, aberrant methylation at TDMRs may adversely 
affect clinical manifestations. 
GTF2A1L (NM_006872) encodes homo sapiens general transcription 
factor IIA, 1-like, formerly known as ALF. Synthesis of eukaryotic mRNA 
requires the assembly  and stability of RNA polymerase II and various general 
transcription factors. This gene encodes a germ cell-specific counterpart of 
the large (alpha/beta) subunit of general transcription factor TFIIA that is able 
to stabilize the binding of TATA-binding protein (TBP) to DNA and may be 
uniquely important to testis biology. 16-18 The gene is also selectively 
transcribed in reproductive tissues. GTF2A1L is coexpressed in late 
pachytene spermatocytes and in haploid round spermatids with TBP-related 
factor 2, and that these proteins form stable complexes in testis extracts. 19 
Aberrant DNA methylation at TDMRs has raised concerns about the 
status of male fertility. In this study, we have confirmed the TDMR of the 
GTF2A1L promoter by applying matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) to human testicular tissue. 
We also describe TDMR methylation patterns of GTF2A1L CpG islands, 
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characterize the methylation status of TDMR in some cases of male infertility, 
and discuss the associated ART outcomes. 
 
Materials and Methods 
Patients and samples 
This study was approved by the Ethics Committee of the Kanazawa University 
Graduate School of Medical Science. All participants granted informed 
consent for this study. Patients (n = 86) with azoospermia in ejaculate were 
recruited between May 2006, and April 2011 and patients with abnormal 
karyotypes or Y chromosome microdeletions were excluded from the study, 
as described previously.20 Testicular tissue specimens were obtained from 
patients who underwent either a diagnostic testicular biopsy or sperm retrieval 
from testicular tissues to evaluate histology while attempting testicular biopsy 
or microdissection TESE. Histological examination of at least 50 seminiferous 
tubules was performed as previously described.21 The most advanced 
spermatogenetic cell that was identified in each analysis determined the 
histological classification of the sample. Men with azoospermia who were 
found to have normal sperm upon histological examination of testis samples 
were classified as having normal spermatogenesis.  
 
Patient categorization 
Patients were classified into five groups by histological diagnosis: normal 
spermatogenesis (NS, n = 26), hypospermatogenesis (HS, n = 17), 
maturation arrest (MA, n = 17), Sertoli cell only phenotype (SCO, n = 21) and 
tubular sclerosis (TS, n = 5). Sperm were present in the tissues of 26 patients 
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who were thought to be secretory azoospermia due to obstructive 
azoospermia. 
 We defined these patients as the control group. The mean ages (mean ± SD) 
of NS(control), HS, MA, SCO, and TS patients were 36.0 ± 5.9, 38.2 ± 3.9, 
34.8 ± 4.1, 35.2 ± 3.7, and 37.2 ± 5.0 years, respectively. 
 
Isolation of genomic DNA and total RNA 
Human genomic DNA from several normal tissues (kidney, muscle, heart, 
brain, and colon tissue) were kindly provided by Professor Hiroki Nagase, 
Department of Advanced Medical Science, Division of Cancer Genetics, 
Nihon University School of Medicine. These samples were obtained by organ 
donation from autopsy cases at the Pathology Division of the Nihon University 
School of Medicine in Tokyo, Japan. When tissues were received through 
organ donation, bereaved families or relatives provided informed, written 
consent.22 Premium Total RNA (Clontech, Mountain View, CA, USA) from 
various normal human tissues was used as a control for the gene expression 
studies. Total RNA and testicular genomic DNA were isolated from each of 
the testicular tissue specimens. TRIzol Reagent (Invitrogen, Carlsbad, CA, 
USA) was used for the extraction of RNA and DNA from the same specimens. 
Total RNA was treated with the TURBO DNA-free kit (Ambion, Austin, TX, 
USA) to remove any residual genomic DNA. Single-stranded cDNA was 
synthesized using a High-Capacity cDNA Archive Kit (Applied Biosystems, 
Foster City, CA, USA). An additional primer pair used for GTF2A1L 
expression was 5'- CTGCCTCAACCCGGTGCCTAAAC -3' and 5'- 
GCTGAACCACTGAGCACTGACTCCAC -3' (product size, 798 bp). The 
 7 
primer pair used for GAPDH expression was 5'- GACCACAGTCCATGCCA 
TCA-3' and 5'- TCCACCACCCTGTTGCTGTA-3' (product size, 453 bp). 
 
Bisulfite treatment and quantitative DNA methylation analysis 
Genomic DNA (1 μg) isolated from testicular specimens was treated with 
sodium bisulfite using the EZ DNA methylation kit (Zymo Research, Orange, 
CA, USA) according to the manufacturer’s instructions. Quantitative DNA 
methylation analysis at single CpG dinucleotides was performed using the 
MassARRAY® Compact system (Sequenom, San Diego, CA, USA) to 
quantify the methylation status of CpG islands in the GTF2A1L promoter, as 
previously described 13. MALDI-TOF MS was used for the high-throughput 
quantitative DNA methylation assay. This system analyzed base-specific 
cleaved amplification products. Each evaluation of methylation was conducted 
using EpiTyper software v1.0 (Sequenom), which is able to generate 
quantitative results for each cleavage fragment (known as a CpG unit), and 
can include individual CpG dinucleotides or aggregates of multiple CpG sites.  
 Putative promoter regions were chosen for this analysis. Arbitrarily 
chosen genomic regions approximately 1 kb upstream of the GTF2A1L start 
site were analysed to determine whether there were promoter-specific 
changes in DNA methylation. Bisulfite-treated DNA was polymerase chain 
reaction (PCR)-amplified using a reverse primer (5’-
CAGTAATACGACTCACTATAGGGAGAAGGCTTT 
AAAACAAACCATAACAACACC-3’) tagged with a T7 promoter sequence. 
The forward primer used was 5’-AGGAAGAGAGGGATTGAGGAA 
ATAATTTGTGAA-3’. The amplification products were transcribed in vitro, 
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base-specifically cleaved by RNase A, and subjected to MALDI-TOF MS for 
the quantitative DNA methylation assay. The graphic data obtained from 
methylation analysis using MassARRAY were expressed as an epigram. DNA 
methylation standards (0%, 20%, 40%, 60%, 80%, and 100% methylated 
genomic DNA) and correction algorithms based on R statistical computing 
environment were used for data correction and normalization.13 
 
LightCycler amplification 
GTF2A1L mRNA was quantified using the LightCycler TaqMan Master 
(Roche Applied Science, Basel, Switzerland). Universal probe no. 62 (Roche) 
with forward primer 5'-TCCTGGTTATCCCATTCATGT-3' and reverse 
GTF2A1L primer 5'- CTGTCACCATAATTGGTACATTGAC-3' were used for 
amplification. As an internal reference standard, GAPDH expression was also 
measured using universal probe no. 60 (Roche) with forward primer 5'-
AGCCACATCGCTCAGACA-3' and reverse primer 5'-
TCAGGAAATTTGACTTTCCATTC-3'. Each universal probe was designed 
according to the Universal Probe Assay Design Center (https://www.roche-
applied-science.com/sis/rtpcr/upl/index.jsp). All PCR reactions were 
performed in a total volume of 20 μL comprising 4 μL of 5x LightCycler 
TaqMan Master (Roche Diagnostics, Mannheim, Germany), 0.3 μL of 10 
μmol/L TaqMan probe, 1 μL of 10 μmol/L each primer, 2 μL of sample cDNA, 
and 11.6 μL of DEPC-treated water. 
Amplification of GTF2A1L and of GAPDH was performed in triplicate 
for each sample. The thermal cycling conditions used were: 10 min at 95°C, 
followed by 50 cycles at 95°C for 10 s and 60°C for 20 s for both GTF2A1L 
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and GAPDH. The number of GTF2A1L and GAPDH transcripts in each 




Data were analysed using GraphPad Prism version 5.04 for Windows 
(GraphPad Software, San Diego, CA, USA; www.graphpad.com). Because of 
the small number of subjects and the skewed distribution of most variable, 
non-parametric statistics were used. The Mann−Whitney U test was used to 
compare mean methylation rates for non-parametric data. Student’s t-test was 
used to examine the correlation between GTF2A1L expression and hormone 
levels. Differences were considered statistically significant at P < 0.05. 
 
Results 
Confirmation of TDMR in GTF2A1L in normal tissues 
The expression of GTF2A1L in several different human tissue types (testis, 
kidney, muscle, heart, brain, and colon) was evaluated by reverse 
transcription (RT)-PCR. The GTF2A1L transcript was detected in testis tissue 
only (Figure 1). 
DNA methylation status of the GTF2A1L regulatory region in several 
different human tissue types was investigated using testes genomic DNA. We 
assayed methylation in testis, kidney, muscle, heart, brain, and colon, and 
focused on the regions upstream of the GTF2A1L gene. These amplicons 
were screened using the MALDI-TOF MS system (MassARRAY® ) to quantify 
methylation at CpG islands. Methylation at CpG islands in the GTF2A1L 
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promoter was lower in the testis (methylation rate: 21.6 ± 2.83%) than in the 
five other tissue types: kidney (85.3 ± 6.21%), muscle (83.1 ± 9.31%), heart 
(84.8 ± 5.66%), brain (88.9 ± 5.85), and colon (84.8 ± 8.16%). These 
differences indicated that there is a TDMR in the 5′-upstream region, 
somewhere within -253 to 43 bp of the transcription start site; this region, a 
301-bp amiplicon, contained a promoter CpG island with 22 CpG 
binucleotides (Figure 2). Therefore, the TDMR of GTF2A1L was classified as 
low methylation at CpG islands in the normal testes. 
 
Quantification of the GTF2A1L methylation state in the testicular 
genome 
We analyzed methylation at the GTF2A1L gene promoter in genomic DNA 
samples from testes using MassARRAY®. Testes DNA from all samples from 
the control group (n = 26) was low methylated at the GTF2A1L promoter, and 
the mean methylation rate was 24.4 ± 10.6% (95% CI 20.1−28.7%). Testis 
DNA from all samples from the HS group (n = 17) was also low methylated, 
and the mean methylation rate was 35.1 ± 12.0% (95% CI 29.0−41.3%). The 
mean methylation rates in patients with HS were significantly high compared 
with the controls (P = 0.029). However, the mean methylation rates in patients 
with MA (n = 17), SCO (n = 21), and TS (n = 5) were 66.5± 0.07% (95% CI 
62.9−70.1%), 76.5± 0.08% (95% CI 73.1−79.9%), and 79.4± 0.07% (95% CI 
70.2−88.7%), respectively. Testes DNA from all samples from the MA, SCO 
or TS group were high methylated (Figure 3). Patients with SCO and TS were 
extreme cases, because the genomic DNA extracted from those testes 
biopsies may not present any germ cell. Although all samples revealed high 
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methylation except NS (control) and part of HS samples, differences in 
methylation level between control and HS groups were statistically significant 
in this study. 
 
Characterization of patients with hypospermatogenesis 
To further characterize the patients with HS, this group was divided into two 
subgroups according to methylation level: low methylation (LM) and high 
methylation (HM). The mean CpG methylation rates were 28.6 ± 6.9% (95% 
CI 24.1−33.0%, n = 12) in the LM group versus 50.9 ± 2.3% (95% CI 
48.0−53.7%, n = 5) in the HM group, and these means were significantly 
different (P = 0.0019, Figure 4A). This finding indicated that some subjects 
with HS exhibited relatively high rates of high methylation in the GTF2A1L 
promoter region. 
 
GTF2A1L expression in the HM and LM groups 
GTF2A1L mRNA was measured using real-time quantitative RT-PCR with 
GAPDH mRNA as an internal reference standard. The GTF2A1L expression 
rate in the control group was 0.91 ± 0.42 (95% CI: 0.74-1.08), whereas the 
rate in the MA, SCO and TS group was 0.18±0.10 (95% CI: 0.1-0.23), 
0.095±0.039 (95% CI: 0.08-0.11) and 0.03±0.02 (95% CI: 0.001-0.060), 
respectively. Both patients with SCO and TS also exhibited high methylation, 
the expression was very low as expected. 
On the other hand, the relative GTF2A1L expression level in the HS group is 
depicted in Figure 4B. Expression of GTF2A1L mRNA was significantly higher 
in the LM group (median=0.9370, 25% percentile= 0.5745, 75% 
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percentile=7.425) than in the HM group (median=0.3460, 25% percentile= 
0.2251, 75% percentile=0.6211) (P = 0.019). These results demonstrated that 
highly methylated TDMRs correlated with low levels of gene expression. 
Therefore, the alteration of methylation within the GTF2A1L promoter may 
greatly affect expression and result in failure of spermatogenesis. 
 
Clinical characteristics of patients with LM and HM 
The general characteristics and clinical parameters of patients with 
hypospermatogenesis are summarized in Tables 1 and 2. These patients 
were classified into two groups based on GTF2A1L methylation state: HM 
(Table 1) and LM (Table 2); the mean level of the patients in each group were 
33.8 ± 2.63 years and 37.7 ± 2.1 years, respectively. Levels of follicle 
stimulating hormone (FSH), luteinizing hormone (LH), and testosterone (T) in 
the LM group were 3.2 ± 0.42 mU/mL, 2.7 ± 0.24 mU/mL, and 5.7 ± 0.99 
ng/mL, respectively. In contrast, the mean level of FSH, LH, and T in the HM 
group were 5.7 ± 0.77 mU/mL, 2.7 ± 0.44 mU/mL, and 4.4 ± 0.30 ng/mL, 
respectively. There was no significant difference in mean levels of FSH (P = 
0.08), LH (P = 0.96), or T (P = 0.12) between the LM and HM groups (Tables 
1 and 2). Following various ARTs, including TESE-ICSI, both groups had 
relatively good outcomes with respect to sperm retrieval and fertilization, 
pregnancy, childbirth rates. We observed that aberrant methylation of the 
GTF2A1L promoter was not correlated with reproductive outcome following 
TESE-ICSI procedures. Moreover sperm proven control group (n=26) 





 Numerous CpG islands containing TDMR are potential methylation 
sites in normal tissues. In this study, methylation at the GTF2A1L CpG island 
was apparently low in testes samples with normal spermatogenesis; however, 
aberrant methylation at the GTF2A1L CpG island was associated with 
hypospermatogenesis in some azoospermic patients. We revealed that the 
aberrant methylation of TDMRs was associated with human spermatogenesis. 
However, there were only five patients exhibiting relatively high methylation at 
the GTF2A1L CpG island. These numbers might be unlikely to provide 
sufficient statistical power; however, all other subjects, including patients with 
MA, SCO and TS, exhibited high methylation, and low methylation at the 
GTF2A1L promoter is thought to be the normal status in TDMR. Although 
larger numbers of male infertility subjects may be necessary to detect the 
influence of aberrant methylation on hypospermatogenesis incidence, these 
relatively higher methylation in five patients can yield meaningful aspects. 
Previously, CpG islands were thought to be almost entirely 
unmethylated, except within imprinted regions and on the inactive X 
chromosome.23 However, accumulating evidence suggests that methylation of 
TDMRs is associated with modulated gene expression24-26 and impairment of 
spermatogenesis.13, 22, 27 
Unlike imprint genes, many TDMRs may play a role in cellular identity 
and tissue-specific regulation of genome function. Moreover, they may be 
broadly distributed in intragenic and intergenic regions that have CpG islands. 
Approximately 4% of more than 5000 autosomal genes with unmethylated 
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CpG island promoters were methylated in normal peripheral blood.28 Aberrant 
TDMR methylation may increase the prevalence of male infertility and be 
included in idiopathic male infertility. 
TESE is a powerful technique used to retrieve sperm from patients with 
azoospermia. ARTs are regularly used to facilitate fertilization and pregnancy. 
ART may be associated with epigenetic changes in imprint genes that can 
lead to human disease. Various artificial procedures may be implicated in 
susceptibility to epigenetic defects such as Beckwith−Wiedemann syndrome 
and Angelman syndrome after ART.29 However, the absolute incidence of 
imprinting disorders is very small.30-32 
On the other hand, epigenetic regulation of the germline has recently 
become clearer a candidate process resulted in male infertility. Tissue-specific 
CpG island methylation was identified at developmental gene loci, which 
became demethylated during differentiation to adult tissues.33 , 34  Moreover, 
high CpG density were mostly unmethylated, and low CpG density were 
preferential targets for de novo methylation using 5-methyl cytosine antibody 
study.35 
Additionally, testicular spermatozoa from men with abnormal 
spermatogenesis often have methylation defects, further supporting an 
association between ARTs and the occurrence of imprinting errors.30 Studies 
of the methylation levels of paternally and maternally methylated imprinted 
genes and aberrant methylation imprints revealed a significant association 
with abnormal semen parameters, but did not seem to influence ART 
outcomes.36 
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In the present study, sperm retrieval and fertilization, pregnancy, child 
birth rates were relatively high. An aberrant expression of GTF2A1L was due 
to aberrant methylation of GTF2A1L TDMR in testicular DNA; however, these 
aberrations did not cause serious damage in testicular spermatozoa 
recovered via TESE procedures. One possible explanation for this finding was 
that aberrant TDMR methylation was thought to result in weak CpG island 
promoters, which were preferential targets for de novo methylation. 
The GTF2A1L protein is co-expressed in late pachytene spermatocytes 
and in haploid round spermatids 19, which may form part of a transcriptional 
network that is vital for the completion of meiosis and for the preparation of 
post-meiotic differentiation.37 
Hypospermatogenesis is characterized histologically by a reduced 
number of spermatozoa in any tubule.21 Although some post-meiotic failure is 
believed to result from aberrant methylation in promoters of some testis-
specific genes, the genetic regulation of post-meiotic spermiogenesis remains 
unclear (e.g., germ cell-specific epigenetic processes, including histone to 
protamine exchange in haploid spermatids or genomic imprinting in a parent). 
Once germ cells complete meiosis, male infertility caused by aberrant 
methylation could be overcome using TESE. 
In summary, we demonstrated that aberrant TDMR methylation at the 
GTF2A1L promoter may have caused a decrease in GTF2A1L expression 
that was associated with hypospermatogenesis. We suggest that TESE is a 
valuable procedure to retrieve sperm from patients with hypospermatogenesis. 
However, our conclusion must be explored in a larger patient population to 
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Figure 1. Tissue-specific expression of GTF2A1L in normal human tissues. 
cDNAs were prepared from total RNA isolated from testis, kidney, muscle, 
heart, brain, and colon tissues. GAPDH was used as the internal standard for 
comparison.  
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Figure 2. Chromosomal location of GTF2A1L. This map is based on the 
March 2006 human reference sequence (NCBI Build 36.1). GTF2A1L is 
shown as an arrow, with an arrowhead indicating the direction of transcription. 
CpG islands are shown with the number of CpGs. The amplicon was 
designed from -258 to +41 (299 bp) from the transcription start site. 
Figure 3.  Rate of methylation status in patients characterized histological 
diagnosis. 
Normal spermatogenesis as control (NS, closed circles, n = 26),   
hypospermatogenesis (HS, closed squares, n = 17), maturation arrest 
phenotype (MA, closed triangles, n = 17), Sertoli cell only phenotype (SCO, 
inverted closed triangles, n = 21) and tubular sclerosis (TS, closed diamonds, 
n = 5).  Asterisk indicates statistically significant difference in values (P<0.05). 
Figure 4 
Classification of high- and low-methylation TDMR groups in patients with 
hypospermatogenesis. (A) Box & Whiskers plot (Min to Max) of patients with 
hypospermatogenesis subdivided according to GTF2A1L methylation rate: 
low methylation (LM, n = 12) and high methylation (HM, n = 5). (B) The 
relative expression level of GTF2A1L in patients with hypospermatogenesis 
and low methylation (LM, n = 12) or high methylation (HM, n = 5). Asterisk 







Table 1 Clinical features of HS patients with high methylation
Age(years) FSH(mU/mL) LH(mU/mL) Testosterone(ng/mL) TESE Sperm Retrieval ICSI Fertilization Pregnancy Childbirth
34 2.25 2.42 4.6 yes yes yes yes yes yes
41 3.4 3.29 8.2 yes yes yes yes yes yes
42 N/P N/P N/P yes yes yes yes yes yes
31 4.23 2.7 3.71 yes yes yes yes yes yes
29 2.8 2.2 6.2 yes yes yes yes yes yes
HS=hypospermatogenesis; TESE=testicular sperm extraction including microdissection; ICSI=intracytospermic sperm injection; N/P=not performed  
Table 2 Clinical features of HS patients with low methylation
Age(years)FSH(mU/mL) LH(mU/mL) Testosterone(ng/mL) TESE Sperm Retrieval ICSI Fertilization Pregnancy Childbirth
31 2.8 1 4.1 yes yes yes yes no no
31 3.4 2.2 3.8 yes yes yes yes yes yes
32 7.2 5.4 6.9 yes yes yes yes yes yes
45 5.4 2.5 4.5 yes yes yes yes no no
35 3 3.1 5.1 yes yes yes yes yes yes
38 4.5 1.5 3.7 yes yes yes yes no no
54 5.4 0.8 4.4 yes yes yes yes yes yes
36 6.7 4 4.1 yes yes yes yes yes yes
58 N/P N/P N/P yes yes yes yes yes yes
38 4.93 2.06 4.7 yes yes yes yes yes yes
34 11.81 2.42 2.9 yes yes N/P N/P N/P N/P
41 7.21 4.64 4.2 yes yes yes yes yes yes
HS=hypospermatogenesis; TESE=testicular sperm extraction including microdissection; ICSI=intracytospermic sperm injection; N/P=not performed  
